| Literature DB >> 28993458 |
John Graham-Brown1, Catherine Hartley1, Helen Clough2, Aras Kadioglu3, Matthew Baylis2,4, Diana J L Williams5.
Abstract
Fasciola hepatica is a parasitic trematode of global importance in livestock. Control strategies reliant on anthelmintics are unsustainable due to the emergence of drug resistance. Vaccines are under development, but efficacies are variable. Evidence from experimental infection suggests that vaccine efficacy may be affected by parasite-induced immunomodulation. Little is known about the immune response to F. hepatica following natural exposure. Hence, we analyzed the immune responses over time in calves naturally exposed to F. hepatica infection. Cohorts of replacement dairy heifer calves (n = 42) with no prior exposure to F. hepatica, on three commercial dairy farms, were sampled over the course of a grazing season. Exposure was determined through an F. hepatica-specific serum antibody enzyme-linked immunosorbent assay (ELISA) and fluke egg counts. Concurrent changes in peripheral blood leukocyte subpopulations, lymphocyte proliferation, and cytokine responses were measured. Relationships between fluke infection and immune responses were analyzed by using multivariable linear mixed-effect models. All calves from one farm showed evidence of exposure, while cohorts from the remaining two farms remained negative over the grazing season. A type 2 immune response was associated with exposure, with increased interleukin-4 (IL-4) production, IL-5 transcription, and eosinophilia. Suppression of parasite-specific peripheral blood mononuclear cell (PBMC) proliferation was evident, while decreased mitogen-stimulated gamma interferon (IFN-γ) production suggested immunomodulation, which was not restricted to parasite-specific responses. Our findings show that the global immune response is modulated toward a nonproliferative type 2 state following natural challenge with F. hepatica This has implications in terms of the timing of the administration of vaccination programs and for host susceptibility to coinfecting pathogens.Entities:
Keywords: multivariable regression modeling; natural challenge; parasitology; veterinary immunology; veterinary vaccine development; zoonotic infections
Mesh:
Substances:
Year: 2017 PMID: 28993458 PMCID: PMC5736823 DOI: 10.1128/IAI.00607-17
Source DB: PubMed Journal: Infect Immun ISSN: 0019-9567 Impact factor: 3.441
FIG 1Antibody PP values of individual animals over the study period for the three dairy farms (farms A to C). The diagnostic positive cutoff value (PP = 20%) is denoted by a horizontal line. Month of sampling denotes the time point for each sequential visit to each farm.
FIG 2Change in antibody PP values (ΔAb) over the course of infection for farm A. Positive values indicate an increase in the Ab PP value from one time point to the next, and negative values denote a decrease in the Ab PP value compared to that for the previous month. Values from 1 month prior to seroconversion (−1) are considered separately from other seronegative values (−ve), as infection may have been present at this time point, but the animals had not seroconverted. In experimentally infected animals, seroconversion occurs at 2 to 4 weeks postinfection (42).
Multivariable linear mixed-effect model outputs for anti-F. hepatica antibody PP values as response variables
| Model, type of data used | Explanatory variable ( | Coefficient value (β) | SE | |
|---|---|---|---|---|
| lme_1, all data | Farm B | −0.687 | 0.077 | <0.001 |
| Farm C | −0.874 | 0.087 | <0.001 | |
| Days of exposure | 0.005 | <0.001 | <0.001 | |
| Eϕ/ml | 0.0001 | 0.00004 | 0.024 | |
| CD8 cells/ml | 0.0002 | <0.0001 | 0.016 | |
| WC1 cells/ml | −0.0001 | 0.00004 | 0.028 | |
| SomAg | −0.006 | <0.003 | 0.024 | |
| lme_2, farm A (positive cohort) | Days of exposure | 0.027 | 0.003 | <0.001 |
| SomAg | −0.012 | 0.005 | 0.039 | |
| [ConA] IFNγ | −0.0001 | <0.00006 | 0.026 | |
| [ConA] IL-4 | 0.0005 | 0.0002 | 0.039 | |
| [SomAg] IL-5 | 0.003 | 0.001 | 0.012 | |
| lme_3, farms B and C (negative cohorts) | Farm C | −0.201 | 0.086 | 0.029 |
| Days of exposure | 0.004 | <0.001 | <0.001 | |
| CD4 cells/ml | −0.0001 | 0.00004 | 0.010 | |
| CD8 cells/ml | 0.0004 | 0.0001 | <0.001 | |
| SomAg | −0.007 | 0.003 | 0.042 |
Statistically significant (P < 0.05) explanatory variables (x) are shown with corresponding coefficient (β) and standard error (SE) values to describe their respective relationships with Ab. Values are rounded to 3 decimal places, or 1 significant figure. For cytokine data, brackets indicate which antigen-stimulated culture condition is referenced, i.e., ConA or SomAg.
Multivariable linear mixed-effect model outputs for the change in antibody PP values as a response variable
| Model, type data used | Explanatory variable ( | Coefficient value (β) | SE | |
|---|---|---|---|---|
| lme_4, farm A (postseroconversion) | Days of exposure | −0.354 | 0.107 | 0.004 |
| SomAg | −2.794 | 1.211 | 0.034 | |
| TegAg | 2.254 | 1.064 | 0.049 | |
| [ConA] IL-4 | 0.012 | 0.050 | 0.033 | |
| [SomAg] IL-5 | 0.071 | 0.029 | 0.026 | |
| lme_5, farms A to C (seronegative values) | Farm B | −12.009 | 4.675 | 0.015 |
| Farm C | −14.760 | 5.096 | 0.006 | |
| CD8 cells/ml | 0.027 | 0.009 | 0.008 | |
| SomAg | −0.621 | 0.276 | 0.027 | |
| TegAg | 0.712 | 0.248 | 0.005 |
Statistically significant (P < 0.05) explanatory variables (x) are shown with the coefficient (β) and standard error (SE) values to describe their respective relationships with ΔAb. Values are rounded to 3 decimal places. For cytokine data, brackets indicate which antigen-stimulated culture condition is being referenced, i.e., ConA or SomAg.
FIG 3Peripheral blood eosinophil counts for individual animals over the study period for the three dairy farms (farms A to C). Month of sampling denotes the time point for each sequential sampling visit.
Linear mixed-effects model structures
| Linear mixed-effect model | Response variable ( | Box-Cox value (λ) | Type(s) of data analyzed | Initial fixed-effect explanatory variable(s) ( | Final explanatory variables ( |
|---|---|---|---|---|---|
| lme_1 | Ab | −0.2 | All data | Farm + days of exposure + age + wt + leukocyte counts + CD4/CD8 ratio + PBMC proliferation (44.98) | Farm + days of exposure + Eϕ + CD4 + CD8 + WC1 + SomAg proliferation + TegAg proliferation (37.99) |
| lme_2 | Ab | 0.2 | Farm A | Days of exposure + age + wt + leukocyte counts + CD4/CD8 ratio + PBMC proliferation + PBMC cytokines (166.04) | Days of exposure + Eϕ + SomAg proliferation + IFN-γ [ConA] + IFN-γ [SomAg] + IL-4 [ConA] + IL-10 [Med] + IL-10 [SomAg] + IL-2 [ConA] + IL-5 [SomAg] (145.57) |
| lme_3 | ΔAb | Nil | Seropositive values; farm A | See lme_2 (354.80) | Days exposure + CD4 + WC1 + SomAg proliferation + TegAg proliferation +IL-4 [ConA] + IL-5 [SomAg] (329.74) |
| lme_4 | Ab | −0.2 | Farms B and C | See lme_1 (38.29) | Farm + days of exposure + SomAg proliferation + Eϕ + CD4 + CD8 + WC1 (26.06) |
| lme_5 | ΔAb | Nil | Seronegative values; farms A to C | See lme_1 (653.12) | Farm + CD4 + CD8 + CD4/CD8 ratio + SomAg proliferation + TegAg proliferation (640.33) |
| lme_6 | ΔAb | Nil | Farms B and C | See lme_1 (580.03) | Eϕ + CD8 (561.09) |
The response variable (Y) indicates the subject of each respective model. The Box-Cox value (λ) is the optimal transformation factor for the response variable to ensure linear fit to the proposed fixed-effect variables. Where “Nil” is indicated, transformation was not required. For initial fixed-effect explanatory variables, “leukocyte counts” refers collectively to leukocyte count data (eosinophils [Eϕ], neutrophils, and CD4+, CD8+, WC1+, and CD14+ PBMCs) per milliliter of peripheral blood, and “PBMC proliferation” refers to PBMC proliferation data (ConA-, SomAg-, and TegAg-stimulated cultures), while “PBMC cytokines” refers to all available PBMC cytokine production and transcription data (IFN-γ, IL-4, and IL-10 production and IL-2 and IL-5 relative gene transcription). For cytokine data present as final explanatory variables, brackets indicate which antigen-stimulated culture condition is being referenced, i.e., medium control (Med), ConA, SomAg, or TegAg. Time series plots of the immunological data included in these models are included in the supplemental material.